Does persistency truly equate to compliance?

Clinical and Experimental Ophthalmology

Volumn 35, Issue 7, 2007, Pages 593-

  Best, Stephen J ^a  

^a Auckland Eye   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; EYE DROPS; PROSTAGLANDIN DERIVATIVE;

BLINDNESS; DIABETIC RETINOPATHY; DIAGNOSTIC ERROR; DRUG UTILIZATION; EARLY DIAGNOSIS; EDITORIAL; EVIDENCE BASED MEDICINE; GLAUCOMA; HUMAN; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

GLAUCOMA; HUMANS; OPHTHALMIC SOLUTIONS; PATIENT COMPLIANCE;

EID: 34848852238     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2007.01600.x     Document Type: Editorial

References (6)

1. Rait JL, Adena MA. Persistency rates for prostaglandin and other hypotensive eyedrops: Population-based study using pharmacy claims data. Clin Experiment Ophthalmol 2007; 35: 602-611.
2. Wilensky, J et al. Measurement of persistence and adherence to regimens of IOP-lowering medications using pharmacy claim data. Am J Ophthalmol 2006; 141; S28-33.
3. Gaskin BJ, Carroll SC, Gamble G, Goldberg I, Danesh-Meyer HV. Glaucoma management trends in Australia and New Zealand. Clin Experiment Ophthalmol 2006; 34: 208-12.
4. Carroll SC, Gaskin BJ, Goldberg I, Danesh-Meyer HV. Glaucoma prescribing trends in Australia and New Zealand. Clin Experiment Ophthalmol 2006; 34: 213-8.
5. Wensor, MD et al. Prevalence of Glaucoma in the Melbourne VIP. Ophthalmology 1998; 105: 733-9.
6. Muller A, Vu HT, Ferraro JG, Keeffe JE, Taylor HR. Utilization of eye care services in Victoria. Clin Experiment Ophthalmol 2006; 34: 445-8.